Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is making strides in both clinical and commercial arenas, as detailed in a recent BioMedWire Podcast featuring Executive Co-Chairman and Co-Founder Anthony Durkacz. The company is advancing Lucid-MS, its lead drug candidate for multiple sclerosis, which aims to address mobility damage associated with the disease. Durkacz noted that Quantum BioPharma has filed an investigational new drug application for a Phase 2 clinical trial, potentially marking the first administration of Lucid-MS to human MS patients.
Lucid-MS is a patented new chemical entity that has shown the ability to prevent and reverse myelin degradation in preclinical models. Myelin degradation is the underlying mechanism of multiple sclerosis, and restoring it could slow or halt disease progression. The Phase 2 trial represents a critical step toward validating these preclinical findings in humans.
In addition to its clinical pipeline, Quantum BioPharma is pursuing commercial opportunities with unbuzzd, a product designed to accelerate alcohol metabolism. The company invented unbuzzd and spun out its over-the-counter version to Unbuzzd Wellness Inc. (UWI), led by industry veterans. Quantum BioPharma retains a 19.84% ownership stake in UWI as of March 31, 2026, and is entitled to royalty payments: 7% of sales until total payments reach $250 million, after which the royalty drops to 3% in perpetuity. The company also retains 100% of the rights to develop similar products or alternative formulations for pharmaceutical and medical uses.
The dual strategy of combining clinical-stage pharmaceutical development with commercially available products positions Quantum BioPharma to generate revenue while advancing its pipeline. This approach could provide a financial buffer as the company navigates the lengthy and costly drug development process. For the industry, the progress of Lucid-MS represents a potential new treatment option for multiple sclerosis, a condition affecting millions worldwide. The unbuzzd product addresses alcohol misuse and metabolic health, areas with significant market demand.
Durkacz emphasized the importance of this combined strategy during the podcast, highlighting how the commercial success of unbuzzd could support the company's broader mission. The royalty structure with UWI ensures ongoing revenue if sales meet targets, while the retained rights allow Quantum BioPharma to explore pharmaceutical applications of the technology.
Investors and stakeholders can find more details in the full article at IBN.fm. The latest news and updates regarding Quantum BioPharma are available in the company's newsroom at IBN.fm/QNTM.
